- Home
- SANG vs OMER Comparison
SANG vs OMER Comparison
Compare SANG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- OMER
- Stock Information
- Founded
- SANG 1984
- OMER 1994
- Country
- SANG Canada
- OMER United States
- Employees
- SANG N/A
- OMER N/A
- Industry
- SANG Computer Software: Programming Data Processing
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- OMER Health Care
- Exchange
- SANG Nasdaq
- OMER Nasdaq
- Market Cap
- SANG 189.6M
- OMER 188.1M
- IPO Year
- SANG 2021
- OMER 2009
- Fundamental
- Price
- SANG $6.00
- OMER $3.08
- Analyst Decision
- SANG
- OMER Strong Buy
- Analyst Count
- SANG 0
- OMER 5
- Target Price
- SANG N/A
- OMER $18.00
- AVG Volume (30 Days)
- SANG 2.7K
- OMER 901.8K
- Earning Date
- SANG 05-08-2025
- OMER 08-06-2025
- Dividend Yield
- SANG N/A
- OMER N/A
- EPS Growth
- SANG N/A
- OMER N/A
- EPS
- SANG N/A
- OMER N/A
- Revenue
- SANG $238,264,000.00
- OMER N/A
- Revenue This Year
- SANG N/A
- OMER N/A
- Revenue Next Year
- SANG $2.91
- OMER $468.75
- P/E Ratio
- SANG N/A
- OMER N/A
- Revenue Growth
- SANG N/A
- OMER N/A
- 52 Week Low
- SANG $4.08
- OMER $2.95
- 52 Week High
- SANG $7.99
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- SANG 60.10
- OMER 37.11
- Support Level
- SANG $5.61
- OMER $2.95
- Resistance Level
- SANG $6.37
- OMER $3.60
- Average True Range (ATR)
- SANG 0.10
- OMER 0.23
- MACD
- SANG 0.02
- OMER 0.05
- Stochastic Oscillator
- SANG 54.88
- OMER 15.63
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.